Form 8-K - Current report:
SEC Accession No. 0001683168-25-001754
Filing Date
2025-03-20
Accepted
2025-03-20 17:15:22
Documents
15
Period of Report
2025-03-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cns_8k.htm   iXBRL 8-K 30107
2 OPINION OF ARENTFOX SCHIFF LLP cns_ex0501.htm EX-5.1 13346
3 GRAPHIC image_002.jpg GRAPHIC 3239
  Complete submission text file 0001683168-25-001754.txt   227533

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cnsp-20250320.xsd EX-101.SCH 3017
5 XBRL LABEL FILE cnsp-20250320_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE cnsp-20250320_pre.xml EX-101.PRE 22360
17 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3802
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 25757768
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)